Some authors advocate that certain neuromuscular diseases, such as Duchenne muscular dystrophy (DMD) and congenital myotubular myopathy, might belong to this group, so that these patients may be less responsive to therapeutic myostatin inhibition [86, 88]. The gene discussed is MSTN; the disease is neuromuscular disease.